Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-...

2025-05-20 20:00 2661

Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality

SHANGHAI and HONG KONG, April 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-04-26 08:30 4270

Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025

SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-04-24 10:26 3569

Antengene to Present Results From Four Cutting Edge Preclinical Studies at AACR 2025 with Focuses Including AnTenGagerTM TCEs and Synthetic Lethality

SHANGHAI and HONG KONG, March 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-03-26 16:28 2906

Antengene Announces 2024 Full-Year Financial Results, Proprietary Programs Advancing to Pivotal Trials with Accelerating Multi-market Revenue Ramp Up

SHANGHAI and HONG KONG, March 21, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", ...

2025-03-21 19:29 4947

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 202...

2025-03-05 13:00 2451

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 202...

2025-03-05 13:00 2637

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

* XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adultpatients with ...

2025-02-13 17:30 3656

Antengene Presents Results from Two Late-Stage Clinical Studies of Selinexor at ASH 2024

SHANGHAI and HONG KONG, Dec. 10, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-12-10 08:30 2990

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2024-11-28 13:04 3610

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 09:08 2567

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-11-06 08:30 2706

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

* This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the th...

2024-10-18 10:35 4260

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2024-10-07 13:14 3019

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approv...

2024-09-23 17:42 4876

Antengene Announces 2024 Interim Financial Results, Highlights Progress in R&D and Commercialization

SHANGHAI and HONG KONG, Aug. 23, 2024 /PRNewswire/ -- Antengene Corporation (6996.HK) today announc...

2024-08-23 12:32 4964

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approv...

2024-08-06 08:00 3032

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM)...

2024-07-05 21:18 8745

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health I...

2024-06-26 16:44 5258

Antengene To Present One Oral and Four Abstracts at ASCO 2024

* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody ...

2024-05-24 08:30 3775